Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 13/20 | 0.56 |
| ▸ | MMEL1 | Q495T6 | 8/20 | 0.46 |
| ▸ | ACE | P12821 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19688110 | 1.00 | MME (0.56) | MMEMMEL1ACE | |
| SCHEMBL19688107 | 0.94 | MME (0.59) | MMEMMEL1ACE | |
| SCHEMBL18922289 | 0.94 | MME (0.59) | MMEMMEL1ACE | |
| SCHEMBL15467603 | 0.92 | MME (0.57) | MMEMMEL1ACE | |
| SCHEMBL19788077 | 0.92 | MME (0.57) | MMEMMEL1ACE | |
| SCHEMBL21351247 | 0.91 | MME (0.51) | MMEMMEL1ACE | |
| SCHEMBL21350796 | 0.91 | MME (0.59) | MMEMMEL1ACE | |
| SCHEMBL19687853 | 0.91 | MME (0.59) | MMEMMEL1ACE | |
| SCHEMBL15466725 | 0.89 | MME (0.62) | MMEMMEL1ACE | |
| SCHEMBL19788119 | 0.89 | MME (0.62) | MMEMMEL1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312537-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-11634413-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220106300-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-04-07 | — | — | US | disclosed |
| US-9670186-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106300-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885MMEL1 240/4885ACE 3/4885 |
| US-11634413-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885MMEL1 240/4885ACE 3/4885 |
| US-20230312537-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885MMEL1 240/4885ACE 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.